2021
DOI: 10.1016/j.jaccas.2021.06.006
|View full text |Cite
|
Sign up to set email alerts
|

Pacemaker Treatment for Apical Hypertrophic Cardiomyopathy in the Setting of an Apical Ventricular Aneurysm

Abstract: We describe the case of a patient with apical hypertrophic cardiomyopathy with concomitant apical aneurysm. We measured the aneurysmal cavity pressure using the pressure guidewire system. The patient underwent implantable cardioverter-defibrillator treatment successfully to reduce the pressure gradient between the aneurysmal cavity and the true left ventricle. ( Level of Difficulty: Intermediate. )

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 10 publications
0
1
0
Order By: Relevance
“…Since the last outpatient echocardiogram four years ago, untreated apical stress likely prompted the development of a left ventricular (LV) aneurysm in our patient. Novel techniques like guidewire measurement of high intracavitary pressure gradients have been proposed as a possible diagnostic tool for myocardial degeneration, aneurysm formation, and arrhythmogenic changes in apHCM [ 6 ]. Medical management for apHCM and aneurysm prevention are uniform, constituting beta-blockers as a first-line option and non-dihydropyridine calcium channel blockers as the second-line option [ 3 ].…”
Section: Discussionmentioning
confidence: 99%
“…Since the last outpatient echocardiogram four years ago, untreated apical stress likely prompted the development of a left ventricular (LV) aneurysm in our patient. Novel techniques like guidewire measurement of high intracavitary pressure gradients have been proposed as a possible diagnostic tool for myocardial degeneration, aneurysm formation, and arrhythmogenic changes in apHCM [ 6 ]. Medical management for apHCM and aneurysm prevention are uniform, constituting beta-blockers as a first-line option and non-dihydropyridine calcium channel blockers as the second-line option [ 3 ].…”
Section: Discussionmentioning
confidence: 99%